An early-stage drug discovery company, Promiliad Biopharma uses a unique combination of genetic engineering and synthetic chemistry to generate novel highly patentable therapeutic agents: novel natural product-like small molecules in combinatorial arrays. Principals of the firm have developed a unique, proprietary approach to the drug discovery: ReBACS (Recombinant Biotechnology Assisted Combinatorial Synthesis). The natural product-based feedstock generated by ReBACS offers a complex and rich structural diversity, simplifies the synthetic challenge in drug discovery and increases the probability of generating new lead compounds. Principals of the firm facilitate the identification of lead compounds, the preparation of focused libraries and the efficient scale up of lead production. Based on Promillad's natural product-like compound arrays, the firm has established internal drug discovery programs that are focused on the development of new antibacterial and antifungal agents.
